Pfizer Q3 Results - Q3 Top Pharma Company Earnings Reports
View Pfizer's Q3 Earnings Report
FiercePharma says: The good news: Pfizer delivered a big increase in third-quarter profits; 26 percent, to be exact. The bad: revenues slipped 3 percent, highlighting the fact that cost-cutting boosted earnings, not product performance. (Nonetheless, sales did beat analyst estimates.) Read more of our coverage here...
Highlights:
- Third-Quarter 2009 Revenues of $11.6 Billion
- Third-Quarter 2009 Reported Diluted EPS(1) of $0.43, Adjusted Diluted EPS(2) of $0.51
- Continues to Execute on Financial and Strategic Commitments; Commenced Wyeth Integration on October 16, 2009 Following Completion of the Acquisition
- Updates Full-Year 2009 Revenue, Reported Diluted EPS(1) and Adjusted Diluted EPS(2) Guidance to Reflect Wyeth Acquisition
Check out Pfizer's current earnings estimates from CNN Money
Pfizer's Website http://www.pfizer.com/home/
Related Articles:
Pfizer/Wyeth merger could eliminate $3B, R&D jobs
Pfizer plans dramatic increase in new cancer drugs
Generics expected to hit Merck, Pfizer earnings
Pfizer moves to cap retiree health benefits
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: